Boehringer Ingelheim at BIO-Europe 2026
Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website
Boehringer Ingelheim takes part in 4 sessions at BIO-Europe 2026 in Cologne. Its sessions span open innovation in drug discovery, biologics manufacturing and the future of ophthalmology. It also asks whether Most Favoured Nations is a game-changer for biotech dealmakers, alongside Astellas, Bristol Myers Squibb and EUCOPE.
| Organization | BIO-Europe 2026 Attendance |
|---|---|
Boehringer Ingelheim Ingelheim am Rhein, Germany | ◆Platinum Sponsor |
Family-owned pharmaceutical company developing human and animal health medicines. | Panel Mon Nov 9 13:00–13:45 Open Innovation in Action: How Pharma Is Rewiring the Drug Discovery Ecosystem How big drug companies share their collections of test molecules and data with outside scientists to speed up early drug discovery. Talk Tue Nov 10 13:00–14:00 Biologics Manufacturing Excellence How makers of biologics, drugs made in living cells, can expand capacity, clear production bottlenecks and use new technology to work more efficiently. Panel Wed Nov 11 10:00–10:45 Envisioning the future of ophthalmology What new data show about treatments for retinal disease, glaucoma and other eye conditions, and where investors see the most promise. Panel Wed Nov 11 10:00–10:45 Most Favoured Nations: A Game-Changer for Biotech Dealmaker? How the US 'most favoured nation' policy, which ties US drug prices to prices paid abroad, is changing drug deals and European launch plans. |
Instantly find 20 buyers from Boehringer Ingelheim
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EBD Group, Informa Connect or BIO-Europe. Submit a correction